June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 9 | 2020
Byte av Certified Adviser till Redeye AB
Read more
June 9 | 2020
Change of Certified Adviser to Redeye AB
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 28 | 2020
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2020
Kommuniké från årsstämma i 2cureX AB (publ)
Read more
May 28 | 2020
2cureX offentliggör delårsrapport för det första kvartalet 2020
Read more
May 28 | 2020
2cureX publishes interim report for the first quarter of 2020
Read more
May 7 | 2020
2cureX offentliggör årsredovisning för räkenskapsåret 2019
Read more
May 7 | 2020
2cureX publishes the annual report for the fiscal year 2019
Read more
April 28 | 2020
Notice of annual general meeting of 2cureX AB (publ)
Read more
April 28 | 2020
Kallelse till årsstämma i 2cureX AB (publ)
Read more
April 6 | 2020
2cureX, Germany receives an additional grant for adapting IndiTreat® to guide immunotherapy of ovarian cancer patients
Read more
April 6 | 2020
2cureX i Tyskland får bidrag för att anpassa IndiTreat® för vägledning av immunterapi mot äggstockscancer
Read more
April 2 | 2020
2cureX establish clinical partnership with Skåne University Hospital, Sweden
Read more